Frank Wiegand

Vice President Global Medical Affairs & Market Access, Neurosciences


Frank Wiegand MD, PhD is the VP Global Medical Affairs & Market Access, Neurosciences in the Global Commercial Strategy Organization (GCSO) of Janssen Global Services LLC., a Johnson & Johnson Company.

His team of Neurologists, Psychiatrists and Health Economist represent the global Johnson & Johnson Medical Affairs and Market Access organization on the Compound Development teams of the R&D organization. The department covers the broad therapeutic areas of Neurology, Psychiatry and Pain and his team of experienced physicians and health economist work in close collaboration with the Global Strategic Marketing organization to ensure the generation of superior compound development plans, market access and lifecycle strategies for the entire CNS portfolio. In addition his department is responsible for the data dissemination and publication strategies as well as for the scientific review of manuscripts and company sponsored study proposals. Frank is a member of the Neuroscience Review Board which directs the R&D investment and strategies, aiming at the development of highly differentiated and innovative therapeutic solutions in the areas of Alzheimer’s disease, mood disorder, schizophrenia and acute and chronic pain.

Before becoming VP Global Medical Affairs and Market Access, Frank served as Global Medical Affairs Leader Neurology and has made a substantial contribution both to the successful establishment of the Global Medical Affairs function and to the achievements of the various Compound Development Teams he has been a member of. Frank originally joined Johnson & Johnson in 2000 and has held positions of increasing responsibility in Marketing & Sales with Janssen-Cilag in Germany, in Global Strategic Marketing with PGSM, and in Medical Affairs with Ortho-McNeil Janssen Scientific Affairs, USA.

Frank received his M.D. and PhD. from the University of Düsseldorf and completed his fellowship training as Neurologist at the University of Essen in Germany. Frank also obtained extensive additional training in neuropharmacology, specifically cerebral ischemia, from the Humboldt University Berlin, where he worked as post-doctoral fellow with funding from the German Stoke Research Foundation. In 2002 he received a Postgraduate Certificate Business Administration from the Herriot Watt University, Edinburgh, Scotland.

Frank is member of several scientific societies and associations, published multiple peer reviewed journal articles and book chapters and achieved numerous business and leadership awards from Johnson & Johnson.